The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
A legfontosabb adatok
- Ki végzi
- Yunfeng Cheng
- Hol
- Shanghai (Kína)Mind a 4 helyszín megnézéseMég 2 másik országban, 3 helyszínen
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 126 fő, tervezett
- Kezdés
- 2024. júl.
- Várható befejezés
- 2026. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Hydroxychloroquine Oral Tablet
- Eltrombopag
- A regiszteradat frissítve
- 2024. június 28.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people over 15 years old with primary immune thrombocytopenia (ITP, a low platelet count caused by the immune system) who test positive for antinuclear antibodies. It compares HCQ plus eltrombopag with eltrombopag alone.
- Életkor
- Above 15 years old (record lists 15 to 99 Years).
- Nem
- All sexes can join.
- A betegség stádiuma
- Primary ITP with a platelet count below 30×10^9/L within 1 week before joining, or below 50×10^9/L with bleeding within 1 week before joining.
- Korábbi kezelés
- People must have had at least two courses of HD-DXM 40 mg/d ×4 d that failed or were followed by relapse, or standard dose prednisone (1-2 mg/kg/d) for 4 weeks with platelets still below 30×10^9/L, platelets falling as prednisone was reduced, or needing prednisone 30mg to keep platelets up.
- Biomarker vagy leletérték
- Antinuclear antibody positive. Other autoantibodies (such as dsDNA, SSA, SSB, RNP, β 2-GP, ACA, ANCA) must be negative. Clotting tests (prothrombin time, activated partial thrombin time) must be near normal.
A részvétel fő kizáró okai
- Low platelets caused by another disease, such as lupus, myelodysplastic syndrome or antiphospholipid syndrome.
- Past blood clots, serious heart disease, or a long QTc on the heart tracing.
- Past organ transplant or bone marrow transplant from a donor.
- HIV, hepatitis B or hepatitis C infection, G6PD deficiency, or allergy or eye damage from 4-aminoquinoline drugs.
- Pregnant or breastfeeding, or unwilling to use effective birth control; active cancer or cancer treatment within 5 years.
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Age is above 15 years old
- Before randomization, the clinical diagnosis is primary immune thrombocytopenia. The platelet count is less than 30×10\^9 / L within 1 week before enrollment, or platelet count is less than 50×10\^9 / L with bleeding symptoms within 1 week before enrollment
- The antinuclear antibody is positive
- Other autoantibodies (mainly including dsDNA antibodies, SSA, SSB, RNP, β 2-GP, ACA, ANCA) are negative
- Participants who had received at least two HD-DXM 40 mg/d ×4 d, failed or relapsed, or received standard dose prednisone (1-2 mg/kg/d) for 4 weeks, the platelet count remained <30×10 9 / L, or the platelet count normalized but decreased with prednisone tappering off, or prednisone 30mg to maintain the platelet number
- Prothrombin time does not exceed ± 3s of the normal value ranget, activated partial thrombin time is not outside normal range ± 10s; no history of coagulopathy except ITP; (6)Understand the study procedures and sign the written informed consent form
Ki nem vehet részt
- With evidence of malignant tumor activity, or receiving anti-tumor treatment within 5 years prior to the screening
- Secondary thrombocytopenia caused by myelodysplastic syndrome, immune diseases such as systemic lupus erythematosus, early aplastic anemia, atypical reanemia, antiphospholipid syndrome, thrombotic thrombocytopenic purpura and various other causes
- The participant has experienced any arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism), or clinical symptoms and medical history indicate thrombophilia
- A medical history of parenchymal organ transplantation or allogeneic bone marrow transplantation
- Being allergic to 4-aminoquinoline compounds
- Having evidence of Human Immunodeficiency Virus (HIV)/ hepatitis C virus(HCV)/ hepatitis B virus(HBV) infection (HIV antibody or HCV antibody is positive, HBV surface antigen is positive, or HBV surface antigen is negative but HBV-DNA indicating viral replication
- With liver cirrhosis or portal hypertension
- Congestive heart disease, including New York Heart Association (NHYA) Grade III / IV, occurred within 3 months prior to screening, arrhythmia requiring medication or myocardial infarction, or arrhythmia known to increase the risk of thrombotic events (such as atrial fibrillation), or corrected QT interval (QTc) is longer than 450 ms, or QTc> 480 ms in paricipants with bundle branch block
- Having received any medication affecting platelet function ( Including but not limited to aspirin, aspirin-containing complexes, clopidogrel, salicylates, and / or non-steroidal anti-inflammatory drugs NSAIDs ) or anticoagulant therapy for over consecutive 3 days within 2 weeks before screening
- With Glucose-6-phosphate dehydrogenase deficiency
- Glutamate transaminotransferase (ALT) or glutamate transaminase (AST) is higher than 1.5 times the upper limit of normal value (ULN), or total bilirubin or blood creatinine is higher than 1.2 times the ULN
- With retinal or visual field changes caused by 4-aminoquinoline compounds
- Participants being pregnant or lactating, or with potential fertility, reluctance to use effective contraception within the entire trial cycle and within 28 days after the end of the trial (or within 28 days after premature withdraw)
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 15 és 99 év között vagy?
Helyszínek itt: Kína
Még 2 másik országban, 3 helyszínen
- Qingpu Branch of Zhongshan Hospital, Fudan UniversityShanghai, KínaContact: Fanli HuaRésztvevőt keres
- Shanghai Jinshan HospitalShanghai, KínaContact: Yunfeng ChengRésztvevőt keres
- Shanghai Zhongshan HospitalShanghai, KínaContact: Lili JiRésztvevőt keres
- Wusong Hospital, Zhongshan Hospital, Fudan UniversityShanghai, KínaContact: Hongjuan LuRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus thrombopoietin receptor agonists (TPO-RA) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus TPO-RA. The main questions it aims to answer are:
A teljes eredeti leírásKevesebb
Does HCQ plus TPO-RA raise the response rate in participants, compared to TPO-RA alone? Does HCQ plus TPO-RA prolong the response duration in participants, compared to Pred alone? Does HCQ plus TPO-RA decrease the dose of TPO-RA to maintain response in participants, compared to TPO-RA alone? What medical problems do participants have when taking HCQ plus TPO-RA? Researchers will compare HCQ plus TPO-RA with TPO-RA alone to see if HCQ plus TPO-RA works better to treat primary immune thrombocytopenia with positive anti-nuclear antibodies.
Participants will:
Take TPO-RA every day for no more than 24 weeks, adjust the dose of TPO-RA according to the platelet level, with or without HCQ twice a day for 1 year; Visit the clinic once every 1 weeks for the first 8 weeks, and once every 2-4 weeks in the following 10 months for checkups and tests; Keep a diary of their symptoms
A vizsgálat 2 csoportja
- HCQ plus TPO-RA groupA vizsgált kezelés
This group is experiment group. Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count, with HCQ twice a day for 1 year
Kezelés: Hydroxychloroquine Oral Tablet és Eltrombopag
- TPO-RA groupPlacebo, összehasonlításként
This group is control group. Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
Kezelés: Eltrombopag
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- The Efficacy and Safety of Hydroxychloroquine Plus TPO-RA in Antinuclear Antibody-positive Patients With Primary Immune Thrombocytopenia-- The Multicenter, Randomized, Open-labled Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06479291: ki vehet részt
- A regiszteradat frissítve
- 2024. június 28.